Format

Send to

Choose Destination
J Oncol Pharm Pract. 2018 Aug 20:1078155218792364. doi: 10.1177/1078155218792364. [Epub ahead of print]

Subcutaneous auto-administration of trastuzumab following therapeutic education: A case report.

Author information

1
1 Department of Pharmacy, Institut BergoniƩ, Bordeaux, France.
2
2 Department of Oncology, Institut BergoniƩ, Bordeaux, France.

Abstract

Trastuzumab is a monoclonal antibody used to treat human epidermal growth receptor 2 positive (HER2+) breast cancers either by itself or in combination with other chemotherapy medication. Marketing authorization was granted for a subcutaneous form of the antibody in 2014. In this case report, we discuss our experience with a patient who took part in a therapeutic education program on self-administration of trastuzumab. We demonstrate that these types of self-administered injections are not only possible but also are toxicity-free. Based on the tolerance data and our patient's experience, we propose that the current regulations be relaxed regarding the availability of trastuzumab subcutaneous form in order to develop a cheaper "city scheme," i.e. self-administered injections.

KEYWORDS:

Breast cancer; monoclonal antibodies; self-administration

PMID:
30126339
DOI:
10.1177/1078155218792364

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center